Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx zahraničních věcí,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Xx. x. x., č. 46/2008 Xx. m. x. a x. 47/2012 Sb. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx dne 16. xxxxxxxxx 2011 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.1)
S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x souladu s xxxxxxx 34 odst. 3 Xxxxxx xxx 1. ledna 2012 x xxxxx dnem xxxxxxxxx v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu platné xx 1. ledna 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx xxx 19. října 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Příloha X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX A XXXXX DOPINGU XXX XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2012
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx antidopingového xxxxxx všechny Zakázané xxxxx xxxxx považovány xx "Xxxxxxxxxx látky" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 x X3.
LÁTKY X METODY ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX LÁTKY
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, DHEA), testosteron x xxxxxx xxxxxxxxxx x xxxxxxx, ale xx s xxxxxxxx xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-5-en-3β,17α-diol | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx xx ně.
Xxx xxxxx skupiny xxxx sekce: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx není xxxxxxxx xxxxxxx produkovat xxxxxxxxx. ** "endogenní " xx vztahuje x xxxxx, kterou může xxxx produkovat přirozeně. |
S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X PŘÍBUZNÉ LÁTKY
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx faktory xxxx zakázány:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx degradaci bílkovin xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
S3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), formoterolu (xxxxxxxxx 36 mikrogramů xx 24 xxxxx) x xxxxxxxxxxx pokud xxxx podány v xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx než 30 ng/ml xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx způsoben xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx než výše xxxxxxx xxxxxxx.
X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Aminoglutethimid, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, testolacton, xxx xx s xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx ně.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx x omezením pouze xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Receptor xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované AMP x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
S5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. xxxxxxxx, nitrožilní xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx x podobnými xxxxxxxxxxxx účinky. Xxxxxxx xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx specifické Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx xxxxx x té, xxxxx xxx xxxx xxxxxxx xx diuretikum nebo xxxxx maskovací látku.
XXXXXXXX METODY
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx xxxx červených xxxxxxx a jim xxxxxxxxx produktů jakéhokoliv xxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx kyslíku, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (RSR13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxx xxxxxxx xxxxxxxx není.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (např. proteázami) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx 50 xx za 6 xxxxx xxxx xxxxxxxx kromě infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx a xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve xx xxxxxxxxx xxxxxxx xx xxxxxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:
1. Xxxxxxxx nukleových xxxxxxx xxxx jejich xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx SO xx X5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx optických isomerů) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu x xxxxxxx xxxxxx xxxxxxxx použití a xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Stimulancia xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, amifenazol, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (příklady):
Xxxxxxxxx**, xxxxx***, efedrin****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.
* Následující látky xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx podání xxxxxxxxxx (xxxx. xxxxx, oční xxxxxxxx) nebo jeho xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Katin xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči je xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Buprenorfin, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx syntetický delta9tetrahydrokanabinol (XXX) a kanabimimetika (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ x XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
LÁTKY XXXXXXXX X URČITÝCH XXXXXXXX |
X1. XXXXXXX
Alkohol (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx bude provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx pravidla (xxxxxxxxxxxxx xxxxxxx) je 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (UIM)
X2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (xxxxxxx discipliny) (WCBS)
∙ Xxxxx (XXX)
∙ Golf (XXX)
∙ Xxxxxxx x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x snowboard X-xxxxx x "xxx xxx"
∙ Xxxxxxxx a xxxxxxx sporty (XXXX)
∙ Xxxxxxx (XXXX, XXX) (zakázané také Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (UlM)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx, alprenolol, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, celiprolol, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx s xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. nabyl účinnosti xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx xx 20.12.2013.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.